Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome

Conclusions:
After controlling for nausea and other factors, headache exacerbation with DHE infusions is not an independent predictor of poor headache outcome and clinicians should not interpret its presence as a reason to stop treatment. The focus of management should be on controlling nausea as it is the most important modifiable factor in achieving a good headache outcome with an inpatient course of IV DHE for chronic migraine.

Source: Neurology - February 29, 2016 Category: Neurology Authors: Eller, M., Gelfand, A. A., Riggins, N. Y., Shiboski, S., Schankin, C., Goadsby, P. J. Tags: Migraine, Class IV ARTICLE Source Type: research